Olaparib Plus Bevacizumab Prolongs Survival in Advanced Ovarian Cancer

Adding PARP inhibitors to maintenance therapy was shown to prolong progression-free survival in patients with advanced ovarian cancer.

Source: CancerNetwork - October 2, 2019 Category: Cancer & Oncology Authors: Christina Bennett, MS Source Type: news